The European Commission prohibits a leading pharmaceuticals company’s Spanish pricing system (Glaxo Wellcome)

"Commission Decision prohibits Glaxo Wellcome’s Spanish pricing system"*1. Introduction On 8 May 2001 the Commission decided to prohibit the dual pricing system which Glaxo Wellcome (GW) had introduced for all its pharmaceutical products in Spain [1]. According to GW's new sales conditions Spanish wholesalers were required to pay a higher price for Glaxo products which they export to other Member States than the price they pay when reselling the same products for consumption on the domestic market. The system clearly aimed at the reduction of parallel trade within the Single Market. The Commission found that the system partitions the Common Market along national lines, thereby interfering with the principal Community objective of integrating markets. It also reduces price competition

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Annette Kliemann, The European Commission prohibits a leading pharmaceuticals company’s Spanish pricing system (Glaxo Wellcome), 8 May 2001, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 39081

Visites 349

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues